CIA
PTCT icon

Cladis Investment Advisory’s PTC Therapeutics PTCT Stock Holding History

Cladis Investment Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Hold
4,200
– – 0.16% 125
2025
Q4 		$319K Sell
4,200
-1,000
-19% -$72.7K 0.17% 118
2025
Q3 		$319K Hold
5,200
– – 0.18% 119
2025
Q2 		$254K Buy
5,200
+1,200
+30% +$57K 0.16% 121
2025
Q1 		$204K Buy
+4,000
New +$200K 0.15% 125

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cladis Investment Advisory's PTCT Position: Q1 2026 in Review

Cladis Investment Advisory held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 4,200 shares worth $286K. The position accounts for 0.16% of the portfolio, ranked #125.

Cladis Investment Advisory first reported a position in PTCT in Q1 2025 and has held it in 5 quarters since. The position peaked at $319K in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Cladis Investment Advisory held 4,200 shares of PTC Therapeutics worth $286K as of Q1 2026.
  • Cladis Investment Advisory left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up 0.16% of Cladis Investment Advisory's portfolio in Q1 2026, its #125 holding.
  • Cladis Investment Advisory first reported a position in PTC Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Cladis Investment Advisory's PTC Therapeutics position peaked at $319K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Cladis Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.